financetom
Business
financetom
/
Business
/
IMFA approves bonus issue of shares in 1:1 ratio; MD says aim is to be debt free by Q4
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IMFA approves bonus issue of shares in 1:1 ratio; MD says aim is to be debt free by Q4
Nov 26, 2021 8:20 AM

Indian Metals and Ferro Alloys (IMFA) has approved a bonus issue in a 1:1 ratio. The prices of the alloy ferrochrome have moved from roughly Rs 90,000 in the first quarter to around Rs 1,03,000 in the second quarter and have firmed up a bit in the third quarter as well.

Subhrakant Panda, Managing Director at IMFA commented about the outlook on ferrochrome prices for the second half of this year. “They (prices of ferrochrome) have substantially firmed up in the third quarter, which is ongoing, and we are actually about Rs 1,20,000 plus, and I see that continuing for the remainder of the financial year as well.”

He added that this has resulted in a very strong performance., IMFA’s EBITDA for H1 was a little more than Rs 410 or 415 crore and for the remainder of the year, the firm is looking at the same level of performance as in Q2, or better than that.

Read Here: JSW Steel shares drop 4% on report of tax evasion by company

Speaking about debt, Panda said the company’s priorities are very clear—pare down debt, reward shareholders, and build up a kitty for expansion. At the end of Q2, the firms had prepaid about Rs 45 crores of debt and declared the Rs 5 per share interim dividend, he said.

“Besides today's announcement of a 1:1 bonus issue, we are also going to prepay about Rs 120 crore of debt before the end of the quarter, and that will make us effectively net debt-free,” he added.

According to Panda, the idea is to become debt-free by the next quarter. Moreover, the company is building a kitty to take up 100,000 tonne per annum expansion project at Kalinganagar, he added.

For full management commentary, watch the video.

Follow our live blog for more stock market updates

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Global investment in fusion energy rises the most since 2022
Global investment in fusion energy rises the most since 2022
Jul 21, 2025
WASHINGTON, July 21 (Reuters) - Global fusion energy investment grew by $2.64 billion in the year since last July, an industry group said in an annual industry survey on Monday, but companies said they need much more money to take the industry commercial. The investment rise took place in places including the United States, the EU, Japan, China and Britain...
Sarepta to pause gene therapy Elevidys shipments in the US
Sarepta to pause gene therapy Elevidys shipments in the US
Jul 21, 2025
July 21 (Reuters) - Sarepta Therapeutics ( SRPT ) said on Monday that it will voluntarily and temporarily pause all shipments of its Elevidys gene therapy for Duchenne muscular dystrophy in the United States. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Sarepta to pause gene therapy Elevidys shipments in US
Sarepta to pause gene therapy Elevidys shipments in US
Jul 21, 2025
July 21 (Reuters) - Sarepta Therapeutics ( SRPT ) said on Monday that it will pause all shipments of its Elevidys gene therapy in the United States after a muscular dystrophy patient who received a different, experimental treatment died. U.S. regulators on Friday asked Sarepta Therapeutics ( SRPT ) to voluntarily halt shipments of its gene therapy. However, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved